A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Growth hormone secreting pituitary adenomas(GHomas) produce excessive GH, stimulating
excessive insulin like growth factor 1(IGF-1) synthesis in the liver, thus causing multiple
systemic complications. The life expectancy of patients with untreated GHomas is shortened by
ten years. The treatment goal of GHomas is to shrink the tumor volume and normalize GH and
IGF-1. Under current treatment, only 50-70% of patients get remission. Rosiglitazone is a
widely used oral antidiabetic medicine. The investigator's preliminary data showed that
rosiglitazone decreased the synthesis of GH and IGF-1 in rat pituitary tumor cells GH3 and
hepatocytes respectively. The investigator plan to investigate the efficacy of rosiglitazone
in the treatment of patients with GHomas who have not been alleviated by other therapies.